Skip to main content
SLAS2024 Main banner
Sartorius Ad
Back

Dingyin Tao, PhD

National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS), Division of Pre-clinical Innovation (DPI)

Dr. Dingyin Tao received his Ph.D. in Analytical Chemistry from Dalian Institute of Chemical Physics, Chinese Academy of Science (Dalian, China) in 2011. He then joined Johns Hopkins Bloomberg School of Public Health (JHSPH) as the postdoctoral fellow and later became an Assistant Scientist (Research-track Assistant Professor) at the same department, focusing on quantitative proteomics research for biomarker discovery and validation. In 2015, he joined the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) as a senior mass spectrometrist, and later he was promoted to the mass spectrometry team lead. His lab is focusing on novel MS-based high-throughput assay development for drug screen, biomarker discovery and validation, novel high-throughput proteomics sample preparation platform, drug target discovery, antibody and antibody-drug conjugation analysis. So far, he has nearly 20 years’ experience on HPLC, mass spectrometry and proteomics, and has published over 60 peer-reviewed papers and 3 book chapters in prestigious journals, like Sci Transl Med, Nat Commun, Mol Cell Proteomics, Nat Struct Mol Biol, PLoS Pathog, Anal. Chem and more. He has filed four patents so far, and one of them (Compositions and Methods for Detection of Malaria Biomarkers) was licensed to ERADA Technology Alliance in 2018, which is being commercialized as a novel RDT product based on human saliva in the Malaria field.

Disclosure information not submitted.

Presentation(s):